Inspire Medical Systems, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing also reports unaudited quarterly results, including the three months ended December 31, 2020.
Business context
Inspire develops and sells an implantable, closed-loop neurostimulation system for moderate-to-severe obstructive sleep apnea (OSA), primarily for U.S. patients unable to tolerate or benefit from positive airway pressure therapy. The company sells mainly to hospitals and ambulatory surgery centers through a direct sales organization. Its business remains substantially dependent on the Inspire system.
Financial performance and liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $115.4 million | $82.1 million | +40.6% |
| Gross profit / margin | $97.8 million / 84.7% | $68.4 million / 83.4% | Margin +1.3 percentage points |
| Operating expenses | $154.0 million | $103.3 million | +49.0% |
| Operating loss | $(56.2) million | $(34.9) million | Loss widened |
| Net loss | $(57.2) million | $(33.2) million | Loss widened |
| Operating cash flow | $(53.0) million | $(32.8) million | More cash used |
Fourth-quarter 2020 revenue was $46.0 million, versus $26.9 million in fourth-quarter 2019; net loss was $7.5 million, versus $9.1 million. U.S. revenue for full-year 2020 was $106.1 million, up 44.1%; Europe contributed $9.3 million, up 10.5%.
At year-end, cash, cash equivalents and investments totaled $234.4 million, including $190.5 million in cash and cash equivalents. Working capital was $249.1 million; total assets were $281.2 million and stockholders’ equity was $229.7 million. Debt outstanding was $24.5 million, with no remaining availability under the facility. The company reported an accumulated deficit of $237.3 million.
Cash provided by financing activities was $134.1 million, primarily reflecting $124.7 million of net proceeds from an April 2020 common-stock offering. The company used $2.5 million for property and equipment and had $72.7 million in supplier purchase commitments at year-end. Management said existing cash resources were expected to fund operations for at least 12 months.
Material changes versus prior year
- Revenue increased 40.6%, despite disruption from COVID-19 and postponed procedures beginning in March 2020. Surgical volumes recovered through the second half; management said the initial backlog of postponed cases was largely eliminated.
- Gross margin improved to 84.7%, which management attributed primarily to manufacturing efficiencies and higher sales volume.
- Research and development expense more than doubled to $26.1 million, reflecting next-generation system, Bluetooth remote and Inspire Cloud development, among other costs.
- Selling, general and administrative expense rose 41.4% to $127.9 million, driven principally by higher compensation and marketing spending; lower travel expense partly offset the increase.
- In April 2020, the company issued 2.3 million shares in a follow-on offering. Year-end common shares outstanding increased to 27.1 million from 24.1 million.
- All seven U.S. Medicare Administrative Contractors published coverage policies in 2020, subject to criteria. The AMA approved new Category I procedure codes scheduled to take effect January 1, 2022; Medicare payment levels were not yet determined.
Outlook, risks and unusual items
- Management expects net losses for the next several years and expects operating expenses to increase as it expands commercial infrastructure and invests in research and development. No specific revenue or earnings guidance was provided.
- COVID-19 remains a material uncertainty: renewed outbreaks or restrictions could reduce procedures, patient screening and access to providers, and constrain hospital capacity. The company reported no supply-chain disruption to date but cannot assure that will continue.
- Commercial success depends on adoption, adequate reimbursement and continued coverage. Some payors still consider the therapy investigational; reimbursement levels for the new CPT codes remained unresolved.
- The company relies on third-party suppliers, including single-source suppliers, and maintains inventory to reduce interruption risk. Inventory valuation depends on forecasts of demand and product obsolescence; the auditor identified inventory reserves as a critical audit matter. Net inventory was $8.5 million and the reserve for excess and obsolete inventory was $0.1 million.
- Other principal risks include competition, product quality and liability, regulatory compliance, data privacy and security, and the ability to scale sales and operations. The $24.5 million credit facility bears variable interest with a stated floor of 7.60%; interest-only payments run through April 2022, with maturity in March 2024.
- The financial-statement audit and internal-control audit received unqualified opinions. The auditor highlighted the judgment involved in estimating excess and obsolete inventory; the filing reported no material legal proceedings.
Key facts for investors to verify
- Whether procedure volumes, patient screening and revenue growth can withstand further COVID-19 disruption and normalize after the 2020 recovery.
- Whether Medicare reimbursement rates under the new CPT codes support adoption, and whether commercial coverage continues to broaden.
- Whether operating expense growth and cash burn moderate enough to extend the stated cash runway, considering purchase commitments and continuing losses.
- Whether supplier capacity, inventory forecasts and product transitions avoid shortages, obsolescence or additional write-downs.
- Debt service, variable-rate exposure and future dilution needs, given the outstanding credit facility and the company’s continued losses.